N-(4-bromo-2-methylphenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine
C26H27BrN8 — CID 171345126
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-(4-bromo-2-methylphenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine
N-(4-bromo-2-methylphenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine (PubChem CID 171345126) has the molecular formula C26H27BrN8 and a molecular weight of 531.46 g/mol. Its IUPAC name is N-(4-bromo-2-methylphenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine.
Molecular Properties
| Compound Name | N-(4-bromo-2-methylphenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine |
|---|---|
| PubChem CID | 171345126 |
| Molecular Formula | C26H27BrN8 |
| Molecular Weight | 531.46 g/mol |
| Exact Mass | 530.15 |
| IUPAC Name | N-(4-bromo-2-methylphenyl)-2-(3-methyl-2H-indazol-5-yl)-6-(4-methylpiperazin-1-yl)imidazo[1,2-a]pyrazin-3-amine |
| SMILES | Cc1cc(Br)ccc1Nc1c(-c2ccc3n[nH]c(C)c3c2)nc2cnc(N3CCN(C)CC3)cn12 |
| InChI | InChI=1S/C26H27BrN8/c1-16-12-19(27)5-7-21(16)29-26-25(18-4-6-22-20(13-18)17(2)31-32-22)30-23-14-28-24(15-35(23)26)34-10-8-33(3)9-11-34/h4-7,12-15,29H,8-11H2,1-3H3,(H,31,32) |
| InChIKey | VURCKHAPPUVQPA-UHFFFAOYSA-N |
| XLogP | 5.15 |
| TPSA | 77.38 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 35 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 531.46 |
| LogP ≤ 5 | 5.15 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171345126 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.